$BTCY
BIOTRICITY INC. Stock $btcy

$btcy Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223041243 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$2.973M	$2.891M	$2.381M
YoY Change	20.89%	21.41%	31.76%
Cost Of Revenue	$805.0K	$892.0K	$1.101M
YoY Change	-23.86%	-18.99%	63.69%
Gross Profit	$2.168M	$1.999M	$1.280M
YoY Change	54.64%	56.16%	12.84%
Gross Profit Margin	72.92%	69.15%	53.76%
Selling, General & Admin	$2.997M	$3.487M	$4.859M
YoY Change	-31.33%	-28.22%	-11.98%
% of Gross Profit	138.23%	174.43%	379.51%
Research & Development	$453.0K	$697.6K	$828.9K
YoY Change	-48.32%	-15.84%	32.49%
% of Gross Profit	20.89%	34.89%	64.75%
Depreciation & Amortization	$1.489K	$1.489K	$1.489K
YoY Change	0.13%	0.0%
% of Gross Profit	0.07%	0.07%	0.12%
Operating Expenses	$3.450M	$4.185M	$5.713M
YoY Change	-38.98%	-26.74%	-7.05%
Operating Profit	-$1.282M	-$2.186M	-$4.433M
YoY Change	-69.85%	-50.69%	-11.55%
Interest Expense	$790.1K	$753.3K	-$76.07K
YoY Change	-270.11%	-1090.23%	-98.57%
% of Operating Profit
Other Income/Expense, Net	$11.00K	-$143.4K	$2.891K
YoY Change	-109.18%	-5059.53%	-100.69%
Pretax Income	-$2.808M	-$3.691M	-$4.693M
YoY Change	-37.83%	-21.35%	-56.36%
Income Tax
% Of Pretax Income
Net Earnings	-$2.808M	-$3.691M	-$4.693M
YoY Change	-37.83%	-21.35%	-56.36%
Net Earnings / Revenue	-94.45%	-127.65%	-197.05%
Basic Earnings Per Share	-$0.34	-$0.44	-$0.09
Diluted Earnings Per Share	-$0.34	-$0.44	-$90.21K
COMMON SHARES
Basic Shares Outstanding	8.769M shares	8.321M shares	50.43M shares
Diluted Shares Outstanding	8.979M shares	8.796M shares	8.643M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$85.09K	$1.200M	$2.498M
YoY Change	-81.15%	-51.96%	-78.64%
Cash & Equivalents	$85.09K	$1.200M	$2.498M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$2.049M	$2.128M	$1.854M
Prepaid Expenses
Receivables	$1.574M	$1.610M	$2.009M
Other Receivables	$224.9K	$240.0K	$391.6K
Total Short-Term Assets	$3.932M	$5.178M	$6.752M
YoY Change	-17.98%	-23.31%	-51.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.04K	$18.53K	$24.48K
YoY Change	-25.89%	-24.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.554M	$1.646M	$1.301M
YoY Change	-16.14%	26.46%	22144.91%
TOTAL ASSETS
Total Short-Term Assets	$3.932M	$5.178M	$6.752M
Total Long-Term Assets	$1.554M	$1.646M	$1.301M
Total Assets	$5.486M	$6.824M	$8.053M
YoY Change	-17.46%	-15.26%	-42.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.656M	$4.530M	$1.227M
YoY Change	95.34%	269.29%	-24.4%
Accrued Expenses	$2.891M	$2.120M	$1.409M
YoY Change	161.25%	50.45%	31.9%
Deferred Revenue
YoY Change
Short-Term Debt	$7.922M	$6.720M	$1.138M
YoY Change	153.46%	490.51%	-37.85%
Long-Term Debt Due	$1.800M	$1.200M
YoY Change
Total Short-Term Liabilities	$18.62M	$17.82M	$4.389M
YoY Change	155.38%	306.13%	-15.83%
LONG-TERM LIABILITIES
Long-Term Debt	$11.40M	$11.95M	$12.58M
YoY Change	-9.74%	-5.04%	1345.15%
Other Long-Term Liabilities	$2.191M	$2.520M	$1.704M
YoY Change	-0.55%	47.93%	1298.4%
Total Long-Term Liabilities	$13.59M	$14.47M	$14.29M
YoY Change	-8.38%	1.27%	1339.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.62M	$17.82M	$4.389M
Total Long-Term Liabilities	$13.59M	$14.47M	$14.29M
Total Liabilities	$32.21M	$32.30M	$18.68M
YoY Change	45.57%	72.92%	200.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$123.1M	-$120.1M	-$103.0M
YoY Change	14.28%	16.64%
Common Stock	$9.420K	$8.811K	$51.90K
YoY Change	-81.97%	-83.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$27.76M	-$26.73M	-$10.62M
YoY Change
Total Liabilities & Shareholders Equity	$5.486M	$6.824M	$8.053M
YoY Change	-17.46%	-15.26%	-42.28%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$2.808M	-$3.691M	-$4.693M
YoY Change	-37.83%	-21.35%	-56.36%
Depreciation, Depletion And Amortization	$1.489K	$1.489K	$1.489K
YoY Change	0.13%	0.0%
Cash From Operating Activities	-$1.308M	-$2.390M	-$4.451M
YoY Change	-58.86%	-46.3%	37.4%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	193.2K	3.430M	-272.8K
YoY Change	-82.6%	-1357.42%	-101.84%
NET CHANGE
Cash From Operating Activities	-1.308M	-2.390M	-4.451M
Cash From Investing Activities
Cash From Financing Activities	193.2K	3.430M	-272.8K
Net Change In Cash	-1.115M	1.040M	-4.724M
YoY Change	-46.12%	-122.02%	-140.81%
FREE CASH FLOW
Cash From Operating Activities	-$1.308M	-$2.390M	-$4.451M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001630113
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2022Q3	BTCY	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	BTCY	Issuance Of Warrants For Services IssuanceOfWarrantsForServices		usd
	BTCY	Other Expense Regarding Loss On Debt Modification OtherExpenseRegardingLossOnDebtModification		usd
	BTCY	Noncash Lease Expenses NoncashLeaseExpenses		usd
	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities		usd
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue		usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues		usd
	BTCY	Reduction Due To Preferred Shares Redeemed ReductionDueToPreferredSharesRedeemed		usd
CY2023Q1	BTCY	Convertible Preferred Stock ConvertiblePreferredStock		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	BTCY	Operating Lease Right Of Use Asset New Leases OperatingLeaseRightOfUseAssetNewLeases		usd
	BTCY	Operating Lease Right Of Use Asset New Leases OperatingLeaseRightOfUseAssetNewLeases		usd
	BTCY	Operating Lease New Leases OperatingLeaseNewLeases		usd
	BTCY	Operating Lease New Leases OperatingLeaseNewLeases		usd
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions		usd
	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals		usd
	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40761
	dei	Entity Registrant Name EntityRegistrantName	BIOTRICITY INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-0983531
	dei	Entity Address Address Line1 EntityAddressAddressLine1	203 Redwood Shores Parkway
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
	dei	City Area Code CityAreaCode	(650)
	dei	Local Phone Number LocalPhoneNumber	832-1626
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	BTCY
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8768650	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1199725	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	570460	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1610074	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1224137	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	2128196	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2337006	usd
CY2023Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	240211	usd
CY2023Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	588599	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	5178206	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	4720202	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	85000	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	85000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	132930	usd
CY2023Q1	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	96344	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18529	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21506	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1409172	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1587492	usd
CY2023Q3	us-gaap	Assets Assets	6823837	usd
CY2023Q1	us-gaap	Assets Assets	6510544	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6658626	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5042476	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	6717731	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4774468	usd
CY2023Q3	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	1200000	usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2883978	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1008216	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	364028	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	335608	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	17824363	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11160768	usd
CY2023Q3	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	870800	usd
CY2023Q1	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	870800	usd
CY2023Q3	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	11081475	usd
CY2023Q1	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	12178809	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1351448	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	759065	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1167203	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1386487	usd
CY2023Q3	us-gaap	Liabilities Liabilities	32295289	usd
CY2023Q1	us-gaap	Liabilities Liabilities	26355929	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8565795	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8565795	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8508052	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8508052	shares
CY2023Q3	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	244453	shares
CY2023Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	244453	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	8811	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	8753	usd
CY2023Q3	BTCY	Common Stock Shares To Be Issued CommonStockSharesToBeIssued	3955	shares
CY2023Q1	BTCY	Common Stock Shares To Be Issued CommonStockSharesToBeIssued	3955	shares
CY2023Q3	BTCY	Shares To Be Issued SharesToBeIssued	24999	usd
CY2023Q1	BTCY	Shares To Be Issued SharesToBeIssued	24999	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	93338220	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	92844478	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-47387	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-152797	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120053686	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-112570825	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-26729036	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-19845385	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6823837	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6510544	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2891297	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2381389	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5912062	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4437441	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	892019	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	1101152	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1996080	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1932075	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	1999278	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1280237	usd
	us-gaap	Gross Profit GrossProfit	3915982	usd
	us-gaap	Gross Profit GrossProfit	2505366	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3487331	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4480310	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7007546	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8972924	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	697620	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	828914	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1410595	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1650090	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	4184951	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	5309224	usd
	us-gaap	Operating Expenses OperatingExpenses	8418141	usd
	us-gaap	Operating Expenses OperatingExpenses	10623014	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2185673	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4028987	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4502159	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8117648	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	753268	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	403551	usd
	us-gaap	Interest Expense InterestExpense	1413780	usd
	us-gaap	Interest Expense InterestExpense	791940	usd
CY2023Q3	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-596420	usd
CY2022Q3	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-50839	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1153639	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-100909	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-18783	usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-172042	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	82669	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-370266	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	6684	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-40020	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	13132	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-90928	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-143380	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2891	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-129945	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2891	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3690840	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4692548	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7103722	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9468800	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3690840	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4692548	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7103722	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9468800	usd
CY2023Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	190442	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	211819	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	379139	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	459956	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3881282	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4904367	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7482861	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9928756	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	281240	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	465517	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	105410	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	698521	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3600042	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4438850	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7377451	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9230235	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.441
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.441
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.567
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.567
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.853
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.853
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.153
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.153
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8795742	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8795742	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8642937	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8642937	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8774242	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8774242	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8608447	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8608447	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-23411614	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	119285	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	163335	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	281240	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3690840	usd
CY2023Q3	BTCY	Preferred Stock Dividends PreferredStockDividends	190442	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-26729036	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-19845385	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	119285	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	374515	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	105410	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7103722	usd
	BTCY	Preferred Stock Dividends PreferredStockDividends	379139	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-26729036	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-6560418	usd
CY2022Q3	BTCY	Preferred Stock Purchased Back Via Cash PreferredStockPurchasedBackViaCash	-60619	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	175294	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	30287	usd
CY2022Q3	BTCY	Adjustments To Additional Paid In Capital Issuancof Warrants For Services AdjustmentsToAdditionalPaidInCapitalIssuancofWarrantsForServices	77332	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	153338	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	465517	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4692548	usd
CY2022Q3	BTCY	Preferred Stock Dividends PreferredStockDividends	211819	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-10623636	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2144736	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2144736	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	632320	usd
	BTCY	Preferred Stock Purchased Back Via Cash PreferredStockPurchasedBackViaCash	-346046	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	37787	usd
	BTCY	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	-30000	usd
	BTCY	Adjustments To Additional Paid In Capital Issuancof Warrants For Services AdjustmentsToAdditionalPaidInCapitalIssuancofWarrantsForServices	154746	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	302528	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	698521	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9468800	usd
	BTCY	Preferred Stock Dividends PreferredStockDividends	459956	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-10623636	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-10623636	usd
	us-gaap	Profit Loss ProfitLoss	-7103722	usd
	us-gaap	Profit Loss ProfitLoss	-9468800	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	374515	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	302528	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	37787	usd
	BTCY	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	154746	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1153639	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-100909	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	82669	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-370266	usd
	BTCY	Gain Loss Upon Convertible Promissory Notes Conversion And Redemption GainLossUponConvertiblePromissoryNotesConversionAndRedemption	-13132	usd
	BTCY	Gain Loss Upon Convertible Promissory Notes Conversion And Redemption GainLossUponConvertiblePromissoryNotesConversionAndRedemption	90928	usd
	BTCY	Other Expense Regarding Loss On Debt Modification OtherExpenseRegardingLossOnDebtModification	59161	usd
	BTCY	Noncash Lease Expenses NoncashLeaseExpenses	178320	usd
	us-gaap	Depreciation Depreciation	2977	usd
	us-gaap	Depreciation Depreciation	2977	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	411440	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	53732	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-208810	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1010630	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-348388	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	27866	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1062999	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1010684	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4222154	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8490203	usd
	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock	398756	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	119285	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1900000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	12500	usd
	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	1977579	usd
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	773737	usd
	BTCY	Repayments Of Preferred Stock Dividend RepaymentsOfPreferredStockDividend	11967	usd
	BTCY	Repayments Of Preferred Stock Dividend RepaymentsOfPreferredStockDividend	719742	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4758634	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1105998	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	536480	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-9596201	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	92785	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27076	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	570460	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12066929	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1199725	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2497804	usd
	us-gaap	Interest Paid Net InterestPaidNet	1046621	usd
	us-gaap	Interest Paid Net InterestPaidNet	620714	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zQ1t2acVz2Jf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_82D_znKBWJwrJCd1">NATURE OF OPERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biotricity Inc. (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014, under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over on February 2, 2016.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted to building and commercializing an ecosystem of technologies that enable access to this market.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-6
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120100000	usd
CY2023Q3	BTCY	Working Capital Deficiency WorkingCapitalDeficiency	12600000	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	11375690	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	14545805	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	11756563	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1476121	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2355318	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2891297	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2381389	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5912062	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4437441	usd
CY2023Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1174826	usd
CY2023Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1186735	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	953370	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1150271	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	2128196	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2337006	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zwUHQGbl5uJj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_866_zqeZgSc0k5W7">Significant accounting estimates and assumptions</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the condensed consolidated financial statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of stock options</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of warrants</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>BIOTRICITY INC.<br/> NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>SEPTEMBER 30, 2023 (Unaudited)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Expressed in US dollars)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of derivative liabilities</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Functional currency</span></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Useful life of property and equipment</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Provisions</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, considering the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contingencies</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Inventory obsolescence</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Incremental borrowing rate for lease</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>BIOTRICITY INC.<br/> NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>SEPTEMBER 30, 2023 (Unaudited)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Expressed in US dollars)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2883978	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1351448	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	4235426	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1008216	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	759065	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	1767281	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5042476	usd
CY2023Q3	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	565399	usd
CY2023Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	446771	usd
CY2023Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	16455	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	32291	usd
CY2023Q3	us-gaap	Accretion Expense AccretionExpense	26833	usd
CY2023Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4530331	usd
CY2023Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	3435123	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2119545	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1607353	usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue	8750	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6658626	usd
	us-gaap	Accretion Expense AccretionExpense	134013	usd
CY2023Q3	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	15000000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	717071	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3167	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3167	usd
CY2023Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	1995	usd
CY2023Q2	us-gaap	Line Of Credit Facility Revolving Credit Conversion To Term Loan Description LineOfCreditFacilityRevolvingCreditConversionToTermLoanDescription	In assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $
CY2023Q2	us-gaap	Financing Receivable Revolving Converted To Term Loan FinancingReceivableRevolvingConvertedToTermLoan	1200000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Capacity Available For Trade Purchases LineOfCreditFacilityCapacityAvailableForTradePurchases	300000	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1025399	usd
CY2023Q3	us-gaap	Line Of Credit Facility Capacity Available For Trade Purchases LineOfCreditFacilityCapacityAvailableForTradePurchases	300000	usd
CY2023Q3	us-gaap	Line Of Credit Facility Annual Principal Payment LineOfCreditFacilityAnnualPrincipalPayment	1325399	usd
CY2023Q3	us-gaap	Convertible Debt ConvertibleDebt	245326	usd
CY2022Q3	us-gaap	Convertible Debt ConvertibleDebt	25230	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	404596	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	56644	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	12400000	usd
CY2021Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2026-12-21
CY2021Q4	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.105	pure
CY2021Q4	us-gaap	Debt Instrument Date Of First Required Payment1 DebtInstrumentDateOfFirstRequiredPayment1	2022-02-15
CY2021Q4	us-gaap	Debt Instrument Payment Terms DebtInstrumentPaymentTerms	Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. Prepayment of amounts owing under the Credit Agreement are allowed under prescribed circumstances.
CY2021Q4	BTCY	Origination Fee Amount OriginationFeeAmount	120000	usd
CY2021Q4	BTCY	Exit Fees ExitFees	600000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	193437	usd
CY2021Q4	us-gaap	Professional Fees ProfessionalFees	48484	usd
CY2021Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	144953	usd
CY2021Q4	us-gaap	Proceeds From Loans ProceedsFromLoans	12000000	usd
CY2021Q4	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1574068	usd
CY2021Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1042149	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	51724	usd
CY2022Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	50839	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	102666	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	100909	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	364000	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	412426	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	239614	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	9590	shares
CY2021Q4	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	198713	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8565795	shares
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	759065	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	352402	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	642416	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-50033	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	364283	usd
	BTCY	Reduction Due To Preferred Shares Redeemed ReductionDueToPreferredSharesRedeemed	-15049	usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1351448	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	701636	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8508052	shares
CY2023Q3	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	244453	shares
CY2023Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	244453	shares
	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	there is also one share of the Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement and outstanding as at September 30, 2023 and March 31, 2023
	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1.10	pure
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1900000	usd
	BTCY	Change In Fair Valueus Measurement With Reconciliation Recurring Basis Liability ChangeInFairValueusMeasurementWithReconciliationRecurringBasisLiability	-642416	usd
CY2023Q3	BTCY	Convertible Preferred Stock ConvertiblePreferredStock	1257584	usd
	BTCY	Stock Issued During Period Share Conversion Of Convertible Securities StockIssuedDuringPeriodShareConversionOfConvertibleSecurities	36897	shares
	BTCY	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	123347	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	119285	usd
CY2022Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	695	shares
CY2022Q2	us-gaap	Stock Issued1 StockIssued1	7500	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	3796	shares
CY2022Q3	us-gaap	Stock Issued1 StockIssued1	30287	usd
CY2022Q3	BTCY	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	47300	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1307483	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	20884	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1286599	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1005091	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	960521	shares
	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	282209	usd
	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	172557	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	2.79
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	4.80
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0385	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0406	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.171	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.139	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.30
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.92
	BTCY	Expected Forfeiture Attrition Rates ExpectedForfeitureAttritionRates	0.0000	pure
	BTCY	Expected Forfeiture Attrition Rates ExpectedForfeitureAttritionRates	0.0000	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.114	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.114	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1587492	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1242700	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	178320	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	102491	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1409172	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1140209	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1722095	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1330338	usd
	BTCY	Operating Lease Repayment And Interest Accretion OperatingLeaseRepaymentAndInterestAccretion	190864	usd
	BTCY	Operating Lease Repayment And Interest Accretion OperatingLeaseRepaymentAndInterestAccretion	100450	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1531231	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1229888	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	364028	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	335608	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1167203	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1386487	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	112005	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	552293	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	600288	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	565359	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	298714	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1531231	usd
CY2023Q3	us-gaap	Depreciation Depreciation	1489	usd
CY2022Q3	us-gaap	Depreciation Depreciation	1489	usd
	us-gaap	Depreciation Depreciation	2977	usd
	us-gaap	Depreciation Depreciation	2977	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29767	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29767	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8261	usd
	us-gaap	Depreciation Depreciation	2977	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11238	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21506	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18529	usd

Files In Submission

Name	View Source	Status
0001493152-23-041243-index-headers.html	Edgar Link	pending
0001493152-23-041243-index.html	Edgar Link	pending
0001493152-23-041243.txt	Edgar Link	pending
0001493152-23-041243-xbrl.zip	Edgar Link	pending
btcy-20230930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
btcy-20230930_cal.xml	Edgar Link	unprocessable
btcy-20230930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
btcy-20230930_def.xml	Edgar Link	unprocessable
btcy-20230930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BTCY
BIOTRICITY INC. Stock $btcy

2023 Q4 Form 10-Q Financial Statement

#000149315223041243 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTCY BIOTRICITY INC. Stock $btcy

2023 Q4 Form 10-Q Financial Statement

#000149315223041243 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTCY
BIOTRICITY INC. Stock $btcy